News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street Zen upgraded Neumora Therapeutics (NASDAQ:NMRA) from a "strong sell" to a "sell" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $6.57. NMRA shares recently dropped by 7.5%, opening at $1.60, and the company reported …
Wall Street Zen upgraded Alto Neuroscience (NYSE:ANRO) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a target price of $36.62. Shares opened at $32.14, near their 12-month high, and the company reported a quarterly loss of $0.65 …
Neumora Therapeutics (NASDAQ:NMRA) reported a Q2 loss of $0.23 per share, exceeding analyst expectations by $0.01. Despite beating estimates, the stock fell by $0.13 to $1.60 and remains significantly below its 12-month high. Institutional investors own 47.65% of the company, and analysts have a …
This article first appeared on GuruFocus. Group Revenue: EUR1.26 billion for H1 2026, up 17% year-over-year (Q1: EUR591 million; Q2: EUR665 million). EBIT: Approximately EUR105 million in H1 2026, nearly doubled year-over-year. EBIT Margin: 8.3% for H1 2026; 9.5% in Q2 2026 stand-alone. Book-to-Bill …
Sharemaestro market context Trend signal active 52 weeks -15.3%OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have reported an amended beneficial ownership stake in NeuroPace Inc. (NPCE). The entities collectively own 1,505,125 shares, representing 4.4% of NeuroPace's common stock as of June 30, 2026, and share both voting and dispositive power …
An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …
Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has reported a beneficial ownership of 5.0% of Neuronetics, Inc.'s common stock, totaling 3,822,124 shares as of August 13, 2026. This disclosure was made in a new SEC ownership filing …
Neumora Therapeutics (NMRA) reported a diluted loss per share of $0.23 for Q2 2026, representing a net loss of $43.1 million. The clinical-stage biopharmaceutical company narrowed its per-share loss by 30.3% year-over-year compared to Q2 2025. This performance is typical for biopharma companies in …
Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.
Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …
ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …
Chardan Capital has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and increased its price target to $33. This positive outlook suggests continued confidence in the company's prospects.
This article reports on Neumora Therapeutics Inc.'s Form 8K filing for August 14. The filing contains important company information for investors, who should review the full document for complete details. The stock symbol for Neumora Therapeutics Inc. is NMRA, and it experienced a -7.51% …
Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …
Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project …
Neuronetics, Inc. (NASDAQ:STIM) recently reported quarterly results showing better-than-expected revenues of US$42m and smaller statutory losses of US$0.05 per share. Analysts have largely maintained revenue forecasts for 2026 at US$161.8m but significantly reduced loss per share estimates to US$0.35. The average price target has …
Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …
Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …
Balyasny Asset Management and its affiliated entities have reported a 7.14% beneficial ownership stake in Contineum Therapeutics (CTNM) Class A common stock through a Schedule 13G/A filing. This equates to 2,335,550 shares, with sole voting and dispositive power, based on 32,723,877 shares outstanding as …
ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …
This article from Stock Traders Daily analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) focusing on its price dynamics and execution-aware positioning. It identifies a strong near-term sentiment despite broader weak alignment, highlighting an exceptional 142.5:1 risk-reward setup targeting a 44.2% gain. The analysis provides specific …
Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …
This article announces the filing of a Form 8K by NewMarket Corp on August 13. It is a brief news item from Investing.com, likely indicating a significant event or disclosure made by the company to the SEC. The article also includes various market data, …
NewMarket Corporation (NYSE: NEU) has declared a quarterly dividend of $3.00 per share. This dividend is payable on October 1, 2026, to shareholders of record as of September 15, 2026. NewMarket Corporation is a holding company with subsidiaries involved in chemical additives, specialty materials …
Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …
ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …
Search by ticker symbol or company name and select a result to open its chart.